GeneDx Holdings Corp. Class A Common Stock (WGS) Stock
NASDAQ · WGS
86.92
Fundamentals
Market cap
$2.64B
Price / Earnings ratio
-24.8x
Price / Sales ratio
5.8x
Price / Book ratio
10.8x
Return on assets
-16.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
NeutralWGSSeptember 9, 2026
Business WireNeutral
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
WGS

Zacks Investment Research
3 Promising Genomics Stocks in the Spotlight in 2026
NeutralWGSSeptember 8, 2026
Zacks Investment ResearchNeutral
3 Promising Genomics Stocks in the Spotlight in 2026
WGS

Business Wire
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
NeutralWGSSeptember 1, 2026
Business WireNeutral
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
WGS

Business Wire
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
NeutralWGSAugust 24, 2026
Business WireNeutral
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
WGS
Technicals
OscillatorsSell5 Indicators
Moving AveragesSell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
513M339M169M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
628M415M207M0
Revenue to Profit
2025$427.5M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-21.0M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
NeutralWGSSeptember 9, 2026
Business WireNeutral
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
WGS

Zacks Investment Research
3 Promising Genomics Stocks in the Spotlight in 2026
NeutralWGSSeptember 8, 2026
Zacks Investment ResearchNeutral
3 Promising Genomics Stocks in the Spotlight in 2026
WGS

Business Wire
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
NeutralWGSSeptember 1, 2026
Business WireNeutral
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
WGS

Business Wire
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
NeutralWGSAugust 24, 2026
Business WireNeutral
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
WGS

Zacks Investment Research
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
NeutralWGSAugust 19, 2026
Zacks Investment ResearchNeutral
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
WGS

Business Wire
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
NeutralWGSAugust 11, 2026
Business WireNeutral
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
WGS

Business Wire
GeneDx to Participate in Upcoming Investor Conferences
NeutralWGSAugust 6, 2026
Business WireNeutral
GeneDx to Participate in Upcoming Investor Conferences
WGS

MarketBeat
GeneDx Q2 Earnings Call Highlights
NeutralWGSAugust 3, 2026
MarketBeatNeutral
GeneDx Q2 Earnings Call Highlights
WGS

Zacks Investment Research
GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Surpass Estimates
NeutralWGSAugust 3, 2026
Zacks Investment ResearchNeutral
GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Surpass Estimates
WGS

Business Wire
GeneDx Reports Second Quarter 2026 Financial Results
NeutralWGSAugust 3, 2026
Business WireNeutral
GeneDx Reports Second Quarter 2026 Financial Results
WGS
About GeneDx Holdings Corp. Class A Common Stock
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
SectorHealthcare
IndustryHealth Information Services
Employees1,300
CEOMs. Katherine A. Stueland
IPO DateNov 4, 2020
HeadquartersStamford, CT
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Katherine A. Stueland | CEO & Director | 1976 |
| Mr. Kevin Feeley CPA | Chief Financial Officer | 1981 |
| Dr. Bryan M. Dechairo Ph.D. | Chief Technology & Innovation Officer | 1973 |
| Mr. Mark A. Gardner M.B.A. | President | 1966 |
| Ms. Sabrina V. Dunbar | Director of Investor Relations & Communications | — |
| Ms. Heidi C. Chen J.D. | Chief Legal Officer | 1967 |
| Ms. Jami Biliboaca | Chief People Officer | — |
| Ms. Melanie Duquette | Chief Growth Officer | — |
| Ms. Lisa Gurry | Chief Business Officer | — |
| Ms. Linda Genen M.D., M.P.H. | Chief Medical Officer | — |
Fundamentals
Valuation
Market cap$2.64B
Price-to-sales ratio5.81
Price-to-book value10.80
Price-earnings ratio-24.80
Return on Equity-28.00%
Return on Sales-17.00%
Return on Assets-16.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-3.64
Income Statement
Average volume671,459
EBITDA$-48.50M
1 year high (52w)$170.87
1 year low (52w)$32.21
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesSell12 Indicators
What the experts say
3 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$84.67
Est return
3.68%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.9 | -19.5 | -13.5 | -4.0 | -20.5 | +32.0 | -9.2 | +25.0 | +4.2 |



